ESMO 2018 News - Episode 1

OncLive News Network On Location: In Munich Saturday, October 20


We are on site at the Messe in Munich, Germany at the 2018 ESMO Congress!

We’ll be recapping some of the top news presented each day during the meeting—and soon we’ll speak with Dr Ghassan Abou-Alfa on some exciting gastrointestinal cancer abstracts being presented at this year’s meeting.

Welcome to OncLive News Network! I’m Gina Columbus.

In breast cancer, findings of the phase III IMpassion 130 study showed that the addition of atezolizumab to nab-paclitaxel reduces the risk of progression or death compared with nab-paclitaxel alone in patients with PD-L1—positive metastatic triple-negative breast cancer.

The double-blind study evaluated the efficacy and safety of the PD-L1 inhibitor plus chemotherapy versus nab-paclitaxel alone in treatment-naïve patients with metastatic disease. A PFS benefit was observed in both PD-L1—positive patients and in the intent-to-treat population, and the combination was also found to be well tolerated.


Moreover, in breast cancer, the CDK4/6 inhibitor palbociclib combined with fulvestrant led to a clinically meaningful benefit in overall survival in patients with previously treated hormone receptor—positive, HER2-negative advanced breast cancer. The data were reported as part of an analysis of the phase III PALOMA-3 trial, which was the basis of the agent’s FDA approval with fulvestrant in 2016.

Additionally, there was a particular OS benefit in patients who were sensitive to endocrine therapy.


And additionally in breast cancer, treatment with the alpha-specific PI3K inhibitor alpelisib in combination with fulvestrant was found to improve progression-free survival in patients with PI3K-mutant HR-positive, HER2 negative advanced breast cancer, according to findings of the phase III SOLAR-1 trial. The agent was also found to be well tolerated.

Data showed that the PFS was nearly twice as long in patients with PIK3CA mutations who were randomised to receive alpelisib versus placebo.


In non—small cell lung cancer, MET amplification and EGFR C797S mutations are the most commonly observed alterations associated with resistance to first-line osimertinib in patients with EGFR-mutant disease, according to preliminary data of a paired sample analysis of the FLAURA trial.

FLAURA showed a progression-free survival benefit with frontline osimertinib compared with standard TKI therapy with erlotinib or bevacizumab and was the basis for the agent’s FDA approval in April 2018, specifically for patients with NSCLC whose tumors harbor EGFR mutations.

Moreover, no acquired EGFR T790M was detected in the osimertinib arm and no unexpected resistance mechanisms were observed.

For a full review of these topics, please visit

That’s all for today. Thank you for watching OncLive News Network! I’m Gina Columbus.